Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients (PREICU)

Jongmin Lee

Status: Completed

Conditions: Immune Deficiency; Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT03881566

PRESEPSIN_IMMUNODIFFICIENCY

Details and patient eligibility

About

This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.

Enrollment: 119 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged ≥ 19 years
• Appropriate clinical data to enable classification into sepsis
• Written informed consent by the patient or legally authorized representative
• Critical illness consistent with sepsis, to be enrolled within 24 hours of presentation

Exclusion criteria

• No informed consent
• A patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability

Trial design

119 participants in 3 patient groups

Immunocompetent sepsis patients

Description:

Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.

Immunocompromised sepsis patients

Description:

Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.

Patients without sepsis

Description:

Patients who admitted intensive care unit without sepsis